BRIEF published on 12/11/2025 at 23:05, 6 months 6 days ago Xenetic Biosciences Adjourns 2025 Annual Stockholders Meeting Xenetic Biosciences Stockholders Meeting Voting Instructions Quorum 2025 Adjournment
PRESS RELEASE published on 12/11/2025 at 23:00, 6 months 6 days ago Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting Xenetic Biosciences, Inc. adjourns 2025 Annual Meeting of Stockholders due to lack of quorum. Stockholders urged to vote before reconvened meeting on January 8, 2026 Xenetic Biosciences Stockholders Quorum Proxy Vote 2025 Annual Meeting
BRIEF published on 11/19/2025 at 14:50, 6 months 28 days ago Xenetic Biosciences Extends Collaboration with Scripps Research Cancer Treatment Biopharmaceutical DNase I CAR-T Therapy Scripps Research
PRESS RELEASE published on 11/19/2025 at 14:45, 6 months 28 days ago Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform Xenetic Biosciences extends collaboration with Scripps Research to advance DNase-based immuno-oncology treatment for cancers Xenetic Biosciences Immuno-oncology DNase I CAR-T Therapy Scripps Research
BRIEF published on 11/13/2025 at 14:50, 7 months 4 days ago Xenetic Biosciences Reports Q3 2025 Financial Results Financial Results Revenue Increase Clinical Trials Pancreatic Carcinoma DNase Technology
PRESS RELEASE published on 11/13/2025 at 14:45, 7 months 4 days ago Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results Xenetic Biosciences, Inc. reports Q3 2025 financial results, focuses on DNase-based technology for cancer treatment. Secured $3.9 million from offering, advancing collaborations Xenetic Biosciences Cancer Treatment Collaborations DNase Technology Q3 2025 Financial Results
BRIEF published on 10/10/2025 at 15:35, 8 months 7 days ago Xenetic Biosciences Announces $4.5 Million Stock Offering Xenetic Biosciences Biopharmaceutical Immuno-oncology Stock Offering Canaccord Genuity
PRESS RELEASE published on 10/10/2025 at 15:30, 8 months 7 days ago Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock Xenetic Biosciences, Inc. announces pricing of underwritten stock offering, aiming to raise $4.5 million for immuno-oncology technologies. Canaccord Genuity acts as bookrunner Xenetic Biosciences Stock Offering Immuno-oncology Technologies Canaccord Genuity S-3 Registration Statement
BRIEF published on 08/13/2025 at 14:05, 10 months 4 days ago Xenetic Biosciences Reports Q2 2025 Financial Results Financial Results Xenetic Biosciences Q2 2025 DNase I Development Partnership Expansions
PRESS RELEASE published on 08/13/2025 at 14:00, 10 months 4 days ago Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results Xenetic Biosciences, Inc. reports Q2 2025 results, expands partnership with The Scripps Research Institute for DNase I with CAR T-cell therapies and ends quarter with $4.8M cash Financial Results Xenetic Biosciences DNase I The Scripps Research Institute CAR T-cell Therapies
Published on 06/18/2026 at 12:00, 13 minutes ago PJX Resources Announces $6.3M Non-Brokered Private Placement to Explore and Drill Priority Critical Metal and Gold Targets in the Sullivan Mining District in Southeastern British Columbia
Published on 06/18/2026 at 11:30, 43 minutes ago Deadline Extended for 2026 Semmelweis-Richter Journalism Award Applications
Published on 06/18/2026 at 00:00, 12 hours 13 minutes ago LIR Life Sciences Completes Comparative Animal Study Showing Successful Protamine-Enhanced Permeation Transport of Both Semaglutide and Tirzepatide
Published on 06/17/2026 at 23:30, 12 hours 43 minutes ago Polaris Renewable Energy Announces Postponement of Annual Meeting of Shareholders
Published on 06/17/2026 at 22:50, 13 hours 23 minutes ago International Battery Metals Ltd. Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results
Published on 06/18/2026 at 11:30, 43 minutes ago 2026 Climate Transition Barometer: more than one in two European SMEs and mid-caps gain a tangible competitive advantage from decarbonisation (x3 vs. 2023)
Published on 06/18/2026 at 11:00, 1 hour 13 minutes ago Mallia Aesthetics Reports Positive Results from Consumer Study with its Hormone-Free 8T3 Essentials Hair Serum
Published on 06/18/2026 at 11:00, 1 hour 13 minutes ago Traum-Ferienwohnungen Launches Vision 360 to Bring AI-Powered Video Tours to Holiday Homeowners Across Europe
Published on 06/18/2026 at 11:00, 1 hour 13 minutes ago ABB Ltd: ABB share buybacks - June 11, 2026 – June 17, 2026
Published on 06/18/2026 at 09:06, 3 hours 7 minutes ago Eiffage, member of the NSORe joint venture, wins the contract for a converter station for the NSC2 offshore grid connection project in Germany
Published on 06/18/2026 at 08:30, 3 hours 43 minutes ago OPmobility wins first awards with Chinese automaker Leapmotor outside of China
Published on 06/18/2026 at 07:00, 5 hours 13 minutes ago bioMérieux introduces Salmonella testing kit on GENE-UP® TYPER to support root cause analysis in the food industry
Published on 06/17/2026 at 17:40, 18 hours 33 minutes ago Report on share repurchases from 10 to 16 June 2026
Published on 06/17/2026 at 08:45, 1 day 3 hours ago Air Liquide is awarded its largest-ever contract in Spain to care for 90,000 patients living with respiratory conditions at home
